Entering text into the input field will update the search result below

Genmed Holding Corp. (GENM.OB) Expands Rollout to Scotland and Northern England

Jan. 26, 2011 2:31 PM ETGNMK
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Located in Amsterdam, Genmed is focused on the delivery of low cost generic pharmaceutical drugs directly to distribution channels throughout the world. Today, Genmed took a major step towards prominence with the announcement of an expansion plan that will include a rollout to Scotland and Northern England.

The announcement comes on the heels of the January 20 press release that the company’s Irish distribution partner agreed to expand the corporation’s product rollout beyond Ireland.

In addition to the added territories, the distribution partner has also agreed to fund an advertising budget with Genmed’s products being placed within the distributor’s network of more than 1,200 pharmacies and over 150 hospitals throughout the world. This is great news for Genmed shareholders and the international medical community as a whole.

Leading the way at Genmed is Erwin Bouwens who serves as the company’s CEO. Commenting on what this expansion will mean to the future of Genmed, Bouwens was quoted as saying, “The addition of Scotland and Northern England to the rollout schedule is extremely exciting. This development shows the commitment of our distribution partner and expands our footprint in the United Kingdom.”

Currently, Genmed Holding Corp. is trading in the $0.50 range. To learn more about this up-and-coming corporation, visit the company website at: genmed.nl

Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.